Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
133 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Alcohol Addiction - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Alcohol Addiction - Pipeline Review, H1 2016', provides an overview of the Alcohol Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction - The report reviews pipeline therapeutics for Alcohol Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Alcohol Addiction therapeutics and enlists all their major and minor projects - The report assesses Alcohol Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Alcohol Addiction Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Alcohol Addiction Overview 10 Therapeutics Development 11 Pipeline Products for Alcohol Addiction - Overview 11 Pipeline Products for Alcohol Addiction - Comparative Analysis 12 Alcohol Addiction - Therapeutics under Development by Companies 13 Alcohol Addiction - Therapeutics under Investigation by Universities/Institutes 15 Alcohol Addiction - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Alcohol Addiction - Products under Development by Companies 19 Alcohol Addiction - Products under Investigation by Universities/Institutes 21 Alcohol Addiction - Companies Involved in Therapeutics Development 22 AbbVie Inc. 22 Addex Therapeutics Ltd 23 Adial Pharmaceuticals, LLC 24 Arbutus Biopharma Corporation 25 Astraea Therapeutics, LLC 26 AstraZeneca Plc 27 Bionex Pharmaceuticals LLC 28 Curemark, LLC 29 Eli Lilly and Company 30 Ethypharm S.A. 31 Euthymics Bioscience, Inc. 32 Foresee Pharmaceuticals, LLC 33 H. Lundbeck A/S 34 Indivior Plc 35 Johnson & Johnson 36 Kyorin Pharmaceutical Co., Ltd. 37 Lohocla Research Corporation 38 Omeros Corporation 39 Pfizer Inc. 40 RTI International 41 SK Biopharmaceuticals Co., Ltd. 42 Tonix Pharmaceuticals Holding Corp. 43 VM Discovery, Inc. 44 XenoPort, Inc. 45 Zynerba Pharmaceuticals, Inc. 46 Alcohol Addiction - Therapeutics Assessment 47 Assessment by Monotherapy Products 47 Assessment by Combination Products 48 Assessment by Target 49 Assessment by Mechanism of Action 52 Assessment by Route of Administration 54 Assessment by Molecule Type 56 Drug Profiles 58 (disulfiram + selegiline) - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 A-705253 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 ABT-436 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 ADX-71441 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 amitifadine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 arbaclofen placarbil - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 AT-1001 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 baclofen - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 carisbamate - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 CERC-501 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 CM-1212 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Drug to Inhibit Triple Reuptake for Alcohol Dependence - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 FP-007 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 gabapentin enacarbil XR - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 GET-73 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 ibudilast - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 JDTic - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 JNJ-5234801 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 nalmefene - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 naltrexone hydrochloride - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 naltrexone hydrochloride - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 odelepran hydrochloride - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 OMS-527 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 ondansetron hydrochloride - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 PF-04457845 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 saracatinib difumarate - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Small Molecule to Antagonize Ghrelin Receptor for Alcoholism - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 TKM-ALDH2 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 VMD-2202 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Alcohol Addiction - Recent Pipeline Updates 103 Alcohol Addiction - Dormant Projects 121 Alcohol Addiction - Discontinued Products 124 Alcohol Addiction - Product Development Milestones 125 Featured News & Press Releases 125 Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501 125 Dec 09, 2015: MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting 125 Oct 01, 2015: XenoPort Announces Plan to Focus on its Growing HORIZANT Business and Names Vincent J. Angotti Chief Executive Officer and Director 126 Jun 30, 2015: MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 in Alcohol Dependence 127 Jun 25, 2015: XenoPort Announces Initiation by NIAAA of Clinical Trial of HORIZANT in Patients with Alcohol Use Disorder 127 Jun 24, 2015: MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting 128 Jan 11, 2015: XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder 128 Jan 07, 2015: Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder 129 Nov 26, 2014: Biotie: UK's Nice Issues Positive Final Guidance For Selincro 130 Nov 26, 2014: Drug recommended to help cut drink dependence 130 Appendix 132 Methodology 132 Coverage 132 Secondary Research 132 Primary Research 132 Expert Panel Validation 132 Contact Us 132 Disclaimer 133
List of Tables Number of Products under Development for Alcohol Addiction, H1 2016 11 Number of Products under Development for Alcohol Addiction - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Development by Companies, H1 2016 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 Alcohol Addiction - Pipeline by AbbVie Inc., H1 2016 22 Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, H1 2016 23 Alcohol Addiction - Pipeline by Adial Pharmaceuticals, LLC, H1 2016 24 Alcohol Addiction - Pipeline by Arbutus Biopharma Corporation, H1 2016 25 Alcohol Addiction - Pipeline by Astraea Therapeutics, LLC, H1 2016 26 Alcohol Addiction - Pipeline by AstraZeneca Plc, H1 2016 27 Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC, H1 2016 28 Alcohol Addiction - Pipeline by Curemark, LLC, H1 2016 29 Alcohol Addiction - Pipeline by Eli Lilly and Company, H1 2016 30 Alcohol Addiction - Pipeline by Ethypharm S.A., H1 2016 31 Alcohol Addiction - Pipeline by Euthymics Bioscience, Inc., H1 2016 32 Alcohol Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016 33 Alcohol Addiction - Pipeline by H. Lundbeck A/S, H1 2016 34 Alcohol Addiction - Pipeline by Indivior Plc, H1 2016 35 Alcohol Addiction - Pipeline by Johnson & Johnson, H1 2016 36 Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 37 Alcohol Addiction - Pipeline by Lohocla Research Corporation, H1 2016 38 Alcohol Addiction - Pipeline by Omeros Corporation, H1 2016 39 Alcohol Addiction - Pipeline by Pfizer Inc., H1 2016 40 Alcohol Addiction - Pipeline by RTI International, H1 2016 41 Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 42 Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 43 Alcohol Addiction - Pipeline by VM Discovery, Inc., H1 2016 44 Alcohol Addiction - Pipeline by XenoPort, Inc., H1 2016 45 Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 46 Assessment by Monotherapy Products, H1 2016 47 Assessment by Combination Products, H1 2016 48 Number of Products by Stage and Target, H1 2016 50 Number of Products by Stage and Mechanism of Action, H1 2016 53 Number of Products by Stage and Route of Administration, H1 2016 55 Number of Products by Stage and Molecule Type, H1 2016 57 Alcohol Addiction Therapeutics - Recent Pipeline Updates, H1 2016 103 Alcohol Addiction - Dormant Projects, H1 2016 121 Alcohol Addiction - Dormant Projects (Contd..1), H1 2016 122 Alcohol Addiction - Dormant Projects (Contd..2), H1 2016 123 Alcohol Addiction - Discontinued Products, H1 2016 124
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
